infection. Multivariable regression analyses controlled for demographic variables and comorbidities.
PURPOSE:
Patients undergoing autologous breast reconstruction are at high risk of perioperative venous thromboembolic events (VTE). The efficacy of chemoprophylaxis in decreasing VTE is well established but the timing of chemoprophylaxis remains controversial. Many surgeons are reluctant to initiate preoperative chemoprophylaxis due to concerns of bleeding. We compare the incidence of bleeding following preoperative versus postoperative initiation of chemoprophylaxis in microvascular breast reconstruction.
METHODS:
Patients undergoing autologous breast reconstruction from August 2010-July 2016 were reviewed. Initiation of chemoprophylaxis changed from postoperative to preoperative in 2013, dividing subjects into two groups. Patient demographics, comorbidities, and complications were reviewed.
RESULTS:
A total of 196 patients (311 flaps) were included in the study (mean age 51.4, SD 4.9; mean BMI 26). A total of 105 patients (166 flaps) received preoperative enoxaparin 40mg while 91 patients (145 flaps) received postoperative chemoprophylaxis. A total of four patients required hematoma evacuation, overall incidence of 2.04%. No hematomas (0%) occurred in the preoperative chemoprophylaxis group (p=0.045). Six patients received blood transfusions; two in the preoperative group, and four in the postoperative group (1.9% vs 4.4%, p=0.419). There was a total of one flap failure and no documented VTE in all groups.
CONCLUSION:
This study demonstrates that preoperative chemoprophylaxis can safely be used in patients undergoing microvascular breast reconstruction. The higher rate of bleeding in the postoperative group may be related to the onset of action of enoxaparin of 4-6 hours, which allows for intraoperative hemostasis in the preoperative group while possibly potentiating postoperative oozing when administered postoperatively. Saturday, May 6, 2017 study was to identify the incidence of symptomatic VTE in patients undergoing harvest of lower extremity flaps who received standard chemoprophylaxis while hospitalized to identify factors which could change postoperative prophylaxis guidelines.
METHODS:
One hundred twenty-seven consecutive patients undergoing unilateral lower extremity flap harvest from June 2011 to December 2015 were retrospectively evaluated for the development of VTE. Each patient had a flap harvested from the lower extremity and inset into the abdomen or perineum and not the ipsilateral leg/foot/ankle. All patients with symptomatic leg pain received bilateral ultrasonographic evaluation for VTE formation. The contralateral, non-operative leg served as an internal control. Sixty comorbidity-matched patients who underwent perineal tumor extirpation without reconstruction provided an external control.
RESULTS:
Sixty patients were male (47%) with mean age of 52 years. Mean follow-up was 339 days. All patients underwent flap reconstruction for an oncologic defect of the abdomen or perineum with 79% undergoing perineal reconstruction. Most patients underwent anterolateral thigh (41%) or gracilis flap (40%) harvest. Eleven patients developed VTEs in either leg (9%), for a total of 15 episodes of VTE. Of these, 10 were donor site (66%) and 5 were contralateral leg (33%). There was a nonsignificant trend towards increased odds for the formation of donor-site VTE when compared with contralateral lower extremity (OR:1.7;CI:0.80-3.4;p=0.15). Patients who underwent flap harvest had a 9 times higher odds of VTE formation when compared with their comorbidity matched controls who did not undergo flap reconstruction (OR:9.08;CI:1-82.6;p<0.05).
CONCLUSIONS:
The rate of VTE is higher than previously appreciated for reconstructive procedures of the perineum that utilize lower extremity flaps. Routine surveillance or extended prophylaxis may be warranted. University of Utah, Salt Lake City, UT PURPOSE: Although chemoprophylaxis for venous thromboembolism (VTE) has been found safe in several studies, there are currently no established guidelines for chemical prophylaxis among outpatient plastic surgical procedures. Abdominoplasties have one of the highest VTE rates of all plastic surgery procedures with an incidence of 0.3-9%, with the risk doubling with any additional procedure. Although many VTE are not clinically significant, it is a potentially preventable complication that can be life threatening. The aim of this study is to evaluate the safety of prescribing outpatient VTE chemoprophylaxis after body contouring surgery when compared to preoperative METHODS: All abdominoplasty and panniculectomy cases performed by a single surgeon from 2007-2016 were retrospectively reviewed to assess the impact of a change in practice in VTE prophylaxis management in 2012. Group I was the initial practice of a single dose of 5000 Units of preoperative subcutaneous heparin. Group II is the current practice of preoperative subcutaneous enoxaparin 40mg followed by seven days of outpatient 40mg subcutaneous enoxaparin upon discharge. Data collection included demographics, pre-operative risk factors, and Caprini scores. Complications evaluated included bleeding/hematoma, infection, skin dehiscence/necrosis, and VTE.
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RESULTS: 152 patients total with 74 in Group I and 78 in Group II. There were no significant differences between demographics or risk factors between Groups I and II. There was a statistically significant different in procedures performed with a higher number of panniculectomy in Group I and a higher number of Fleur de Lis technique in Group II. There were no significant differences in bleeding/hematoma 1.4% vs. 5.1%(p=0.3), infection 10.8% vs. 9%(p=0.7), seroma 8.1% vs. 9%(p=0.92) or major wound healing 4.1% vs. 5.1% (p=0.16) between the Group I and II. The incidence of VTE in the population was 0.66% with 1 patient, in Group I being diagnosed with a DVT/PE on postoperative day 1. The patient, who had a Caprini score of 5, was initially planned for Group II, but could not receive chemoprophylaxis due to an active bleed from a concurrent gynecologic procedure.
